Skip to main content
Log in

The augmentation of lymphokine-activated killer activity following pulsing of human peripheral blood mononuclear cells with recombinant human interleukin-2

  • Original articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

The short-term exposure of peripheral blood mononuclear cells (PBMC) to recombinant human interleukin-2 (rhIL-2) at 37°C leads to the generation of lymphokine-activated killer (LAK) activity similar in magnitude to that obtained by the exposure of PBMC to rhIL-2 continuously for 3–5 days. In order to investigate whether the required signal for LAK induction occurred during the short exposure to rhIL-2 or at a later point in the induction phase, PBMC were exposed to rhIL-2 for 1 h at 4°C and then exposed to a low-pH wash to remove bound IL-2 from its receptor. PBMC treated in such a way showed increased LAK activity and proliferation compared to cells exposed to rhIL-2 alone. Expression of the p55 (α) subunit of the IL-2 receptor was also increased. In order to cause the augmentation, a lowering of the pH below 4.0 was necessary, and exposure of PBMC to low pH alone (in the absence of rhIL-2) failed to cause activation. Another relevant feature was a transient increase in the expression of the p75 subunit of the IL-2 receptor (β chain) immediately following the exposure to low pH and the release of interferon γ, tumour necrosis factor α and IL-6; activation was blocked by the inclusion of neutralising antisera raised against rhIL-2 and interferon γ, thus demonstrating that the endogenous release of these cytokines is important for activation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Aribia MH, Moire N, Metivier D, Vaquero C, Lantz O, Olive D, Charpentier B, Senik A (1989) Interleukin-2 receptors on circulating natural killer cells and T-lymphocytes: similar in numbers and affinity but different in transmission of the proliferative signal. J Immunol 142: 490

    PubMed  Google Scholar 

  2. Boyum A (1968) Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 21 [Suppl 1]: 77

    PubMed  Google Scholar 

  3. Brooks B, Chapman K, Lawry J, Meager A, Rees RC (1990) Suppression of lymphokine-activated killer (LAK) cell induction mediated by interleukin-4 and transforming growth factor 1: effect of addition of exogenous tumour necrosis factor-alpha and interferongamma and measurement of their endogenous production. Clin Exp Immunol 82: 583

    PubMed  Google Scholar 

  4. Carter CRD, Hancock BW, Rees RC (1991) The induction of lymphokine activated killer activity following short term exposure of PBMC to rhIL-2. Manuscript in preparation

  5. Damle NK, Doyle LV (1987) Interleukin-2 activated human killer lymphocytes: lack of interferon in the development of IL-2-activated killer lymphocytes. Int J Cancer 40: 519

    PubMed  Google Scholar 

  6. Espinosa I, Ortaldo JR, Winkler-Pickett R, Sugamara K, Varesio L, Longo DL (1990) Expression and role of p75 interleukin-2 receptor on human monocytes. J Exp Med 171: 1821

    PubMed  Google Scholar 

  7. Fuji M, Sugamara K, Sano K, Nakair M, Sugita K, Hinuma Y (1986) High affinity receptor-mediated internalisation and degradation of interleukin-2 in human T-cells. J Exp Med 163: 550

    PubMed  Google Scholar 

  8. Fung MR, Scearce RM, Hoffman JA, Peffer WJ, Hammes SR, Kosking JB, Schandt R, Kuziel WA, Haynes DF, Mills GB, Greene WC (1991) A tyrosine kinase physically associates with the subunit of the human IL-2 receptor. J Immunol 147: 1523

    Google Scholar 

  9. Grimm EA, Mazumber A, Zhang HZ, Rosenberg SA (1982) Lymphokine activated killer cell phenomenon. Lysis of natural killer resistant fresh solid tumour cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823

    PubMed  Google Scholar 

  10. Grimm EA, Robb RJ, Neckers LM, Lachman LB, Wilson DJ, Rosenberg SA (1983) Lymphokine activated killer phenomenon: III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine activated killer cells. J Exp Med 158: 1356

    PubMed  Google Scholar 

  11. Herrman F, Cannistra SA, Lindemann A, Blohm D, Ramboldii A, Mertelsmann RH, Griffin JD (1989) Functional consequences of monocyte IL-2 receptor expression induction of IL-1 secretion IFNγ and IL-2. J Immunol 142: 139

    PubMed  Google Scholar 

  12. Holter W, Goldman C, Casabo L, Nelson D, Greene W, Waldemann T (1987) Expression of functional IL-2 receptor by lipopolysaccharide and interferon stimulated human monocytes. J Immunol 138: 2917

    PubMed  Google Scholar 

  13. Horton SH, Oldham RK, Yannelli JR (1990) Generation of human lymphokine-activated killer cells following brief exposure to high dose interleukin-2. Cancer Res 50: 1686

    PubMed  Google Scholar 

  14. Itoh K, Shiiba K, Shimiza Y, Suzuki R, Kamagai K (1985) Generation of activated killer (AK) cells by recombinant interleukin-2 in collaboration with interferon-γ J Immunol 134: 3124

    PubMed  Google Scholar 

  15. McIntyre CA, Chapman K, Reeder S, Dorreen MS, Bruce L, Rodgers S, Hayat K, Screenivasan T, Sheridan E, Hancock BW, Rees RC (1992) Treatment of malignant melanoma and renal cell carcinoma with recombinant human interleukin-2: analysis of cytokine levels in sera and culture supernatants. Eur J Cancer 28: 58

    PubMed  Google Scholar 

  16. Mule JJ, Shu S, Schwarz SL, Rosenberg SA (1984) Adoptive immunotherapy of established pulmonary metastasis with LAK cells and recombinant interleukin-2. Science 225: 1487

    PubMed  Google Scholar 

  17. Mule JJ, Shu S, Rosenberg SA (1985) The antitumour efficacy of lymphokine activated killer cells and recombinant interleukin-2 in vivo. J Immunol 135: 646

    PubMed  Google Scholar 

  18. Ohashi Y, Takeshita T, Nagata K, Mori S, Sugamara K (1989) Differential expression of the IL-2 receptor subunit p55 and p75 on various populations of primary PBMC. J Immunol 143: 3548

    PubMed  Google Scholar 

  19. Ortaldo JR, Mason A, Overton R (1988) Lymphokine activated killer cells: analysis of progenitors and effectors. J Exp Med 164: 1193

    Google Scholar 

  20. Owen-Schaub LB, London WG, Yagita M, Grimm EA (1988) Functional differentiation of human lymphokine-activated killer (LAK) is distinct from expansion and involves dissimilar interleukin-2 receptors. Cell Immunol 111: 235

    PubMed  Google Scholar 

  21. Phillips JH, Lanier LL (1986) Dissection of the lymphokine activated killer phenomenon — relative contribution of peripheral blood natural killer cells and T-lymphocytes to cytolysis. J Exp Med 164: 814

    PubMed  Google Scholar 

  22. Phillips JH, Takeshita T, Sugamara K, Lanier LL (1989) Activation of natural killer cells via the p75 interleukin-2 receptor. J Exp Med 170: 291

    PubMed  Google Scholar 

  23. Press OW, Hanson JA, Farr A, Martin PJ (1988) Endocytosis and degradation of murine anti-human CD3 monoclonal antibody by normal and malignant T-lymphocytes. Cancer Res 48: 2249

    PubMed  Google Scholar 

  24. Ramila P (1988) Cytolysis of tumour necrosis factor(TNF) resistant tumour targets: differential cytotoxicity of monocytes activated by the interferons, IL-2 and TNF. J Immunol 140: 1345

    PubMed  Google Scholar 

  25. Robb RJ, Greene WC (1987) Internalisation of interleukin-2 is mediated by the β chain of the high affinity IL-2 receptor. J Exp Med 165: 1202

    Google Scholar 

  26. Robb RJ, Greene WC, Rusk CM (1984) Low and high affinity cellular reception for IL-2. Amplification for the level of Tac antigen. J Exp Med 160: 1126

    PubMed  Google Scholar 

  27. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan W, Robertson GN, Lee RE, Rubin JT, Seip CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316: 889

    PubMed  Google Scholar 

  28. Sayer TJ, Mason AT, Ortaldo JR (1986) Regulation of human NK cell activity by interferon gamma. Lack of a role in IL-2 mediated augmentation. J Immunol 136: 2176

    PubMed  Google Scholar 

  29. Schaffar L, Dallanegra A, Breittmayer JP, Carrel S, Fehlman M (1988) Monoclonal antibody internalisation and degradative during modification of CD3/T-cell receptor complex. Cell Immunol 116: 52

    PubMed  Google Scholar 

  30. Strieter RM, Remick DG, Lynch JP, Spengler RW, Kunkel SL (1989) Interleukin-2 induced tumour necrosis factor alpha (TNF α) gene expression in human alveolar macrophages and blood monocytes. Am Rev Respir Dis 139: 335

    PubMed  Google Scholar 

  31. Taetle R, Castagnola J, Mendelsohn J (1986) Mechanisms of growth inhibition by anti-transferrin receptors monoclonal antibodies. Cancer Res 46: 1759

    PubMed  Google Scholar 

  32. Takeshita T, Goto Y, Tada K, Nagata K, Hironobu A, Sugamara K (1989) Monoclonal antibody defining a molecule possibly identical to the p75 subunit of the interleukin-2 receptor. J Exp Med 169: 1323

    PubMed  Google Scholar 

  33. Tsudo M, Kitamura F, Miyasaki M (1989) Characterisation of the interleukin-2 receptor β-chain using three distinct monoclonal antibodies. Proc Natl Acad Sci USA

  34. Wahl SM, McCartney-Francis N, Hunt DA, Smith PD, Wahl LM, Katona IM (1987) Monocyte interleukin-2 receptor gene expression and interleukin-2 augmentation of microbicidal activity. J Immunol 139: 1342

    PubMed  Google Scholar 

  35. Weigent MB, Stanton JG, Johnson HM (1983) Interleukin-2 enhances natural killer cell activity through induction of gamma interferon. Infect Immun 41: 992

    PubMed  Google Scholar 

  36. West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thunman GB, Oldham RK (1987) Constant infusion of recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 89

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carter, C.R.D., Hancock, B.W. & Rees, R.C. The augmentation of lymphokine-activated killer activity following pulsing of human peripheral blood mononuclear cells with recombinant human interleukin-2. Cancer Immunol Immunother 35, 264–270 (1992). https://doi.org/10.1007/BF01789333

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01789333

Key words

Navigation